FindTrial
Sign In

Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis

Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis - Systematic review of the seroconversion of anti-citrullinated peptide (CCP) antibodies in rheumatoid arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000056193
Enrollment
Unknown
Registered
2024-11-20
Start date
2024-11-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Sponsors

First Department of Internal Medicine, University of Toyama
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Original paper evaluating the development of anti-CCP antibody after diagnosis of rheumatoid arthritis

Exclusion criteria

Exclusion criteria: 1)Unable to assess frequency of Anti-CCP antibody seroconversion 2)Reviews, meta-analysis papers and Research plan 3)Conference abstracts

Design outcomes

Primary

MeasureTime frame
Seroconversion of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis.—

Secondary

MeasureTime frame
Factors associated with the development of anti-citrullinated peptide (CCP) antibodies in patients with rheumatoid arthritis—

Countries

Japan

Contacts

Public ContactRyoko Asano

University of Toyama Faculty of Medicine The First Department of Internal Medicine

aryoko@med.u-toyama.ac.jp076-434-7287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026